Novo Nordisk said Sept. 30 that adults with overweight or obesity who took its experimental drug CagriSema for a year showed sustained changes in how their brains responded to pictures of high-calorie food. They also reported fewer cravings and less food noise, the constant thoughts about eating that many people describe.
The findings were presented as a late-breaking abstract at the European Association for the Study of Diabetes (EASD) annual meeting in Milan. They have not been published in a peer-reviewed journal, and Novo has not released the number of participants or detailed brain scan results.
